Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H28N2O3.ClH |
Molecular Weight | 380.909 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCCN=C1COC(=O)C(O)(C2CCCCC2)C3=CC=CC=C3
InChI
InChIKey=WXAYTPABEADAAB-UHFFFAOYSA-N
InChI=1S/C20H28N2O3.ClH/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17;/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3;1H
Molecular Formula | C20H28N2O3 |
Molecular Weight | 344.4479 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB00383
Sources: https://www.drugbank.ca/drugs/DB00383
Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers. Daricon was discontinued in USA, but still used worldwide.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1426023 |
9.2 null [pKi] | ||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1426023 |
8.7 null [pKi] | ||
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1426023 |
9.0 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DARICON Approved UseOxyphencyclimine binds the muscarinic acetylcholine receptor. It may block all three types of muscarinic receptors. The muscarinic acetylcholine receptors mediate various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Oxphencyclimine inhibits vagally mediated reflexes by antagonizing the action of acetylcholine. This in turn reduces the secretion of gastric acids in the stomach. |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg single, oral Highest studied dose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: Page: p.13 |
unhealthy n = 5 Health Status: unhealthy Condition: Peptic ulcer Population Size: 5 Sources: Page: p.13 |
|
10 mg 3 times / day multiple, oral (max) Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Peptic ulcer Sources: |
|
5 mg single, intramuscular Studied dose Dose: 5 mg Route: intramuscular Route: single Dose: 5 mg Sources: Page: p.13 |
unhealthy n = 5 Health Status: unhealthy Condition: Peptic ulcer Population Size: 5 Sources: Page: p.13 |
PubMed
Title | Date | PubMed |
---|---|---|
A LONG ACTING ANTICHOLINERGIC-SEDATIVE COMBINATION IN GASTROINTESTINAL DISORDERS. CLINICAL TRIAL OF OXYPHENCYCLIMINE HYDROCHLORIDE WITH PHENOBARBITAL (DARICON PB). | 1964 May |
|
Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. | 1992 Sep 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14143029
In clinical trials oxyphencyclimine hydrochloride (5 mg) was prescribed daily, one tablet three times a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1426023
[3H]NMS binding to M4 receptor was measured at 25°C in a total volume of 1.2 ml using the following incubation buffer: 50 mM sodium phosphate (pH 7.4) enriched with 2 mM MgCI2, 1% bovine serum albumin (except when indicated) and the indicated tracer and drug concentrations. In binding experiments on rat striatum ho-mogenates, the tracer concentration was 0.25 nM and the protein concentration 30-40 ug per assay (about 50 pM binding sites). Under equilibrium conditions (2 h incubation at 25°C) [3H]NMS labelled M,. M, and M4 sites in this brain region. To analyze tracer binding to M4 sites only, striatum homogenates were preincubated for 2 h at 25°C to allow equilibrium binding, then induced tracer dissociation by adding 1 uM atropine. [3H]NMS dissociated from its binding sites after 35 min of isotopic dilution, the residual binding being about 30% of initial binding. R-enantiomer of Oxyphencyclimine displaced binding of [3H]NMS to M4 receptors with pKi of 9.2, whereas binding of its S-enantiomer was less potent.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:11:57 GMT 2023
by
admin
on
Fri Dec 15 16:11:57 GMT 2023
|
Record UNII |
GWO1432WOU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID6045909
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
91164
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | RxNorm | ||
|
C100201
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
GWO1432WOU
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
100000085512
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
m8342
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB03594MIG
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL1495
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
66061
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
DBSALT000812
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
528449
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
204-742-8
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
125-52-0
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
C66284
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |